Gossamer Bio (NASDAQ:GOSS – Get Free Report) and Moderna (NASDAQ:MRNA – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.
Institutional and Insider Ownership
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Volatility & Risk
Gossamer Bio has a beta of 2.28, indicating that its stock price is 128% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Gossamer Bio and Moderna, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 3 | 5 | 0 | 2.30 |
| Moderna | 4 | 15 | 6 | 0 | 2.08 |
Gossamer Bio presently has a consensus price target of $246.40, suggesting a potential upside of 2,090.22%. Moderna has a consensus price target of $120.25, suggesting a potential downside of 37.64%. Given Gossamer Bio’s stronger consensus rating and higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Moderna.
Profitability
This table compares Gossamer Bio and Moderna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -159.49% | N/A | -112.10% |
| Moderna | -110.46% | -25.79% | -15.85% |
Earnings and Valuation
This table compares Gossamer Bio and Moderna”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $78.42 million | 0.88 | -$170.37 million | ($46.56) | -0.24 |
| Moderna | $1.94 billion | 40.14 | -$2.82 billion | ($7.10) | -27.16 |
Gossamer Bio has higher earnings, but lower revenue than Moderna. Moderna is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
About Gossamer Bio
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.
About Moderna
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
